KARYOPHARM THERAPEUTICS INC.
85 WELLS AVENUE, SECOND FLOOR
NEWTON, MA 02459
November 29, 2016
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: | Karyopharm Therapeutics Inc. |
Registration Statement on Form S-3
File No. 333-214489
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Karyopharm Therapeutics, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-214489) (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern time on December 1, 2016, or as soon thereafter as practicable.
Very truly yours, | ||
Karyopharm Therapeutics Inc. | ||
By: | /s/ Christopher B. Primiano | |
| ||
Name: | Christopher B. Primiano | |
Title: | Senior Vice President, Corporate Development, | |
General Counsel and Secretary |